Payment overview · 2025
General Payments
$159.25
4 reported records · 3 companies
Healthcare provider profile · identity verified
Vannarith So, MD, MPH
Allopathic & Osteopathic Physicians|Internal Medicine · LONG BEACH, CA · NPI 1659416584
Verified facts
What the public records show
CMS Open Payments records show Vannarith So, MD, MPH received $159.25 in general payments during 2025 across 4 reported records.
UCB, Inc. accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $96.37 | 60.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.75 | 23.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.13 | 15.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.25 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $49.65 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $46.72 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1264 | 318 |
| Amlodipine Besylate | Amlodipine Besylate | 643 | 169 |
| Losartan Potassium | Losartan Potassium | 436 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 116 |
| Gabapentin | Gabapentin | 399 | 98 |
| Eliquis | Apixaban | 385 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 95 |
| Omeprazole | Omeprazole | 339 | 87 |
| Metformin Hcl | Metformin Hcl | 329 | 88 |
| Lisinopril | Lisinopril | 311 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 69 |
| Famotidine | Famotidine | 249 | 44 |
| Furosemide | Furosemide | 236 | 65 |
| Potassium Chloride | Potassium Chloride | 220 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 52 |
| Meloxicam | Meloxicam | 179 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 175 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 43 |
| Alendronate Sodium | Alendronate Sodium | 141 | 41 |
| Januvia | Sitagliptin Phosphate | 139 | 31 |
| Tramadol Hcl | Tramadol Hcl | 133 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 43 |
| Azithromycin | Azithromycin | 127 | 100 |
| Clonidine Hcl | Clonidine Hcl | 125 | 46 |
| Finasteride | Finasteride | 125 | 24 |
| Allopurinol | Allopurinol | 124 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 23 |
| Nifedipine Er | Nifedipine | 120 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 37 |
| Carvedilol | Carvedilol | 114 | 36 |
| Donepezil Hcl | Donepezil Hcl | 112 | 20 |
| Ibuprofen | Ibuprofen | 106 | 39 |
| Sertraline Hcl | Sertraline Hcl | 102 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 45 |
| Humalog Kwikpen U-100 | Insulin Lispro | 99 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 43 |
| Albuterol Sulfate | Albuterol Sulfate | 89 | suppressed |
| Memantine Hcl | Memantine Hcl | 89 | 12 |
| Montelukast Sodium | Montelukast Sodium | 89 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 87 | suppressed |
| Levetiracetam | Levetiracetam | 87 | 16 |
| Trazodone Hcl | Trazodone Hcl | 85 | 30 |
| Prednisone | Prednisone | 84 | 58 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 11 |
| Olanzapine | Olanzapine | 81 | 18 |
| Lorazepam | Lorazepam | 79 | 30 |
| Propranolol Hcl | Propranolol Hcl | 79 | 14 |
| Baclofen | Baclofen | 78 | 25 |
| Ezetimibe | Ezetimibe | 76 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 28 |
| Simvastatin | Simvastatin | 74 | 25 |
| Lansoprazole | Lansoprazole | 73 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 54 |
| Atenolol | Atenolol | 69 | 15 |
| Ozempic | Semaglutide | 69 | 15 |
| Xarelto | Rivaroxaban | 69 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 44 |
| Risperidone | Risperidone | 61 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 19 |
| Midodrine Hcl | Midodrine Hcl | 60 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 42 |
| Gemfibrozil | Gemfibrozil | 59 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 28 |
| Benazepril Hcl | Benazepril Hcl | 57 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 11 |
| Sucralfate | Sucralfate | 49 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 18 |
| Jardiance | Empagliflozin | 46 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 12 |
| Farxiga | Dapagliflozin Propanediol | 45 | 18 |
| Alprazolam | Alprazolam | 42 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 42 | 15 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Valsartan | Valsartan | 39 | 11 |
| Levofloxacin | Levofloxacin | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 11 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 12 |
| Spironolactone | Spironolactone | 36 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 20 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | 11 |
| Budesonide | Budesonide | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 15 |
| Azelastine Hcl | Azelastine Hcl | 29 | 13 |
| Cephalexin | Cephalexin | 29 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 16 |
| Temazepam | Temazepam | 28 | 15 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Brilinta | Ticagrelor | 26 | 12 |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Diazepam | Diazepam | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 16 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Prolia | Denosumab | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Phenytoin | Phenytoin | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.25 · 4 records | UCB, Inc. | AUSTEDO XR, Briviact, INGREZZA, Nayzilam | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error